PD occurs predominantly in elderly people, who commonly have co-morbidities.1,2,4 A study that followed patients with PD over a 12-year period, concluded that having a higher level of comorbidity during the earlier stages of PD (0–4 years from diagnosis/recruitment) increased the likelihood of early death.1 Beyond 4 years, however, the amount of comorbidity in the population appeared to make little difference.1 Deaths that occur during early-stage PD are most often caused by other factors (e.g., cardiovascular disease) rather than PD itself, since PD symptoms during this period tend to be mild, easily-controlled, and unlikely to have severe adverse effects on health.1

The study also recommended the Charlson Comorbidity Index (CCI)3 as the most appropriate tool for measuring comorbidity in patients with PD; it is quicker to use and produces more consistent results than other currently available assessment methods.1

 

References:
1.Macleod AD, Goddard H, Counsell CE. Co-morbidity burden in Parkinson’s disease: comparison with controls and its influence on prognosis. Parkinsonism Relat Disord 2016; 28: 124–129.

2.Burchill E, Watson CJ, Fanshawe JB, et al. The impact of psychiatric comorbidity on Parkinson’s disease outcomes: a systematic review and meta-analysis. Lancet Reg Health Eur 2024; 39: 100870.

3.Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40 (5): 373–383.

4.von Campenhausen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson’s disease in Europe. Eur Neuropsychopharmacol 2005; 15 (4): 473–490.